Advanced Pharmacology for Prescribers 1st Edition Luu, Kayingo, and
Hass Test Bank
,
,There are 10 multiple-choice questions for each of the 36 chapters in this pharmacotherapy textbook. I
have worked through the chapters systematically, ensuring each question meets your rigorous
standards for clinical application, vignette-based scenarios, and current guideline integration.
SECTION I: FOUNDATIONS OF PRESCRIBING
Chapter 1: Pharmacokinetics and Pharmacodynamics
Question 1 A 78-year-old woman with atrial fibrillation on warfarin (INR 2.5, stable for 6 months) is
started on amiodarone for rhythm control. Two weeks later, she presents with epistaxis and INR 4.8.
What is the primary mechanism for this drug interaction?
A. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
B. Amiodarone displaces warfarin from plasma albumin binding sites
C. Amiodarone induces P-glycoprotein, increasing warfarin clearance
D. Amiodarone inhibits CYP3A4 and CYP2C9, reducing warfarin clearance
Question 2 A 45-year-old man with HIV (CD4 350, undetectable viral load on
efavirenz/tenofovir/emtricitabine) requires initiation of rifampin for latent TB treatment. Which
pharmacokinetic concern is most critical when adding rifampin?
A. Rifampin inhibits CYP3A4, increasing efavirenz toxicity
B. Rifampin induces multiple CYP enzymes and P-glycoprotein, reducing antiretroviral efficacy
C. Rifampin reduces gastric pH, impairing tenofovir absorption
D. Rifampin competes for renal tubular secretion with emtricitabine
Question 3 A 62-year-old man with CKD stage 4 (eGFR 22 mL/min) is prescribed gabapentin 300 mg TID
for neuropathic pain. After 5 days, he presents with severe somnolence and ataxia. Which
pharmacokinetic parameter is most responsible?
A. Decreased volume of distribution in renal impairment
B. Accumulation of active metabolites due to reduced renal clearance
C. Increased bioavailability due to decreased first-pass metabolism
D. Protein binding displacement by uremic toxins
Question 4 A 55-year-old woman with metastatic breast cancer receiving high-dose methotrexate (5
g/m²) develops severe mucositis and pancytopenia 48 hours post-infusion. Her creatinine has doubled
from baseline. Which intervention is most appropriate?
A. Initiate hemodialysis to enhance methotrexate elimination
B. Administer leucovorin rescue and aggressive hydration with urinary alkalinization
C. Administer N-acetylcysteine to restore glutathione stores
D. Discontinue methotrexate and transition to capecitabine
, Question 5 A 34-year-old pregnant woman (32 weeks gestation) with epilepsy controlled on lamotrigine
200 mg BID presents with breakthrough seizures. Her lamotrigine level is subtherapeutic despite
adherence. What is the most likely explanation?
A. Increased renal clearance due to increased GFR in pregnancy
B. Decreased absorption due to delayed gastric emptying
C. Increased hepatic metabolism due to estrogen-induced UGT induction
D. Increased volume of distribution due to increased plasma volume
Question 6 A 68-year-old man with CHF is initiated on carvedilol 3.125 mg BID. After 2 weeks, he
develops worsening dyspnea and peripheral edema. Which pharmacodynamic concept explains this
exacerbation?
A. Unopposed alpha-1 blockade causing fluid retention
B. Acute negative inotropy exceeding compensatory mechanisms
C. Upregulation of beta-receptors causing tachyphylaxis
D. Reflex tachycardia from vasodilation
Question 7 A 50-year-old liver transplant recipient on tacrolimus presents with tremor, headache, and
tacrolimus trough of 22 ng/mL (goal 5-8). He recently started clarithromycin for community-acquired
pneumonia. Which mechanism explains this toxicity?
A. Clarithromycin inhibits CYP3A4 and P-glycoprotein in gut and liver
B. Clarithromycin displaces tacrolimus from albumin binding sites
C. Clarithromycin inhibits renal tubular secretion of tacrolimus
D. Clarithromycin induces UGT enzymes, altering tacrolimus metabolism
Question 8 A 42-year-old woman with treatment-resistant depression is started on tranylcypromine 30
mg daily. After eating aged cheese at dinner, she develops severe headache, hypertension (210/110),
and diaphoresis. Which pharmacodynamic mechanism is responsible?
A. Irreversible MAO inhibition preventing tyramine metabolism
B. Reversible inhibition of serotonin reuptake
C. Direct alpha-1 agonist activity of the MAOI
D. Histamine release from mast cell degranulation
Question 9 A 28-year-old man with Crohn's disease requires infliximab 5 mg/kg IV. The infusion
pharmacist notes the patient is obese (BMI 42, actual body weight 120 kg, ideal body weight 70 kg).
Which weight should be used for dosing?
A. Actual body weight to ensure adequate volume of distribution
B. Ideal body weight to avoid toxicity from increased adipose distribution
C. Adjusted body weight using 40% correction factor
D. Pharmacokinetic monitoring is unnecessary as infliximab has wide therapeutic index
Question 10 A 65-year-old man with atrial fibrillation on dabigatran 150 mg BID presents with acute
ischemic stroke 8 hours after his last dose. CT shows no hemorrhage. The neurology team considers
thrombolysis. Which factor is most relevant to the decision?
Hass Test Bank
,
,There are 10 multiple-choice questions for each of the 36 chapters in this pharmacotherapy textbook. I
have worked through the chapters systematically, ensuring each question meets your rigorous
standards for clinical application, vignette-based scenarios, and current guideline integration.
SECTION I: FOUNDATIONS OF PRESCRIBING
Chapter 1: Pharmacokinetics and Pharmacodynamics
Question 1 A 78-year-old woman with atrial fibrillation on warfarin (INR 2.5, stable for 6 months) is
started on amiodarone for rhythm control. Two weeks later, she presents with epistaxis and INR 4.8.
What is the primary mechanism for this drug interaction?
A. Amiodarone inhibits CYP2C9, reducing warfarin metabolism
B. Amiodarone displaces warfarin from plasma albumin binding sites
C. Amiodarone induces P-glycoprotein, increasing warfarin clearance
D. Amiodarone inhibits CYP3A4 and CYP2C9, reducing warfarin clearance
Question 2 A 45-year-old man with HIV (CD4 350, undetectable viral load on
efavirenz/tenofovir/emtricitabine) requires initiation of rifampin for latent TB treatment. Which
pharmacokinetic concern is most critical when adding rifampin?
A. Rifampin inhibits CYP3A4, increasing efavirenz toxicity
B. Rifampin induces multiple CYP enzymes and P-glycoprotein, reducing antiretroviral efficacy
C. Rifampin reduces gastric pH, impairing tenofovir absorption
D. Rifampin competes for renal tubular secretion with emtricitabine
Question 3 A 62-year-old man with CKD stage 4 (eGFR 22 mL/min) is prescribed gabapentin 300 mg TID
for neuropathic pain. After 5 days, he presents with severe somnolence and ataxia. Which
pharmacokinetic parameter is most responsible?
A. Decreased volume of distribution in renal impairment
B. Accumulation of active metabolites due to reduced renal clearance
C. Increased bioavailability due to decreased first-pass metabolism
D. Protein binding displacement by uremic toxins
Question 4 A 55-year-old woman with metastatic breast cancer receiving high-dose methotrexate (5
g/m²) develops severe mucositis and pancytopenia 48 hours post-infusion. Her creatinine has doubled
from baseline. Which intervention is most appropriate?
A. Initiate hemodialysis to enhance methotrexate elimination
B. Administer leucovorin rescue and aggressive hydration with urinary alkalinization
C. Administer N-acetylcysteine to restore glutathione stores
D. Discontinue methotrexate and transition to capecitabine
, Question 5 A 34-year-old pregnant woman (32 weeks gestation) with epilepsy controlled on lamotrigine
200 mg BID presents with breakthrough seizures. Her lamotrigine level is subtherapeutic despite
adherence. What is the most likely explanation?
A. Increased renal clearance due to increased GFR in pregnancy
B. Decreased absorption due to delayed gastric emptying
C. Increased hepatic metabolism due to estrogen-induced UGT induction
D. Increased volume of distribution due to increased plasma volume
Question 6 A 68-year-old man with CHF is initiated on carvedilol 3.125 mg BID. After 2 weeks, he
develops worsening dyspnea and peripheral edema. Which pharmacodynamic concept explains this
exacerbation?
A. Unopposed alpha-1 blockade causing fluid retention
B. Acute negative inotropy exceeding compensatory mechanisms
C. Upregulation of beta-receptors causing tachyphylaxis
D. Reflex tachycardia from vasodilation
Question 7 A 50-year-old liver transplant recipient on tacrolimus presents with tremor, headache, and
tacrolimus trough of 22 ng/mL (goal 5-8). He recently started clarithromycin for community-acquired
pneumonia. Which mechanism explains this toxicity?
A. Clarithromycin inhibits CYP3A4 and P-glycoprotein in gut and liver
B. Clarithromycin displaces tacrolimus from albumin binding sites
C. Clarithromycin inhibits renal tubular secretion of tacrolimus
D. Clarithromycin induces UGT enzymes, altering tacrolimus metabolism
Question 8 A 42-year-old woman with treatment-resistant depression is started on tranylcypromine 30
mg daily. After eating aged cheese at dinner, she develops severe headache, hypertension (210/110),
and diaphoresis. Which pharmacodynamic mechanism is responsible?
A. Irreversible MAO inhibition preventing tyramine metabolism
B. Reversible inhibition of serotonin reuptake
C. Direct alpha-1 agonist activity of the MAOI
D. Histamine release from mast cell degranulation
Question 9 A 28-year-old man with Crohn's disease requires infliximab 5 mg/kg IV. The infusion
pharmacist notes the patient is obese (BMI 42, actual body weight 120 kg, ideal body weight 70 kg).
Which weight should be used for dosing?
A. Actual body weight to ensure adequate volume of distribution
B. Ideal body weight to avoid toxicity from increased adipose distribution
C. Adjusted body weight using 40% correction factor
D. Pharmacokinetic monitoring is unnecessary as infliximab has wide therapeutic index
Question 10 A 65-year-old man with atrial fibrillation on dabigatran 150 mg BID presents with acute
ischemic stroke 8 hours after his last dose. CT shows no hemorrhage. The neurology team considers
thrombolysis. Which factor is most relevant to the decision?
